Handelsavisen
prelaunch
Companies ›Health Care ›BTAD.NS
BT
BTAD.NS — NSE (India) Pharmaceuticals

Beta Drugs Ltd

$1 361,60
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

(a) Capital structure and liquidity for Beta Drugs Ltd show no dilution risk, as shares outstanding remain unchanged between basic and diluted shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. (b) Profitability and returns data are not available for Beta Drugs Ltd, and no industry_config preferred metrics or cohort medians can be compared at this time. (c) Segment and geographic exposure details are not disclosed in the available data, and no revenue concentration metrics are provided to assess risk from specific markets or product lines. (d) Growth trajectory data is limited, as no outlook numeric deltas or revenue history are available to project future performance. (e) Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. Dilution risk is currently low, with no adjustments applied to valuation metrics. (f) No recent events, filings, or transcripts are available to inform the company's current strategic or operational direction.

Business. Beta Drugs Ltd (BTAD.NS) is a pharmaceutical company headquartered in India that operates within the Healthcare sector. The firm is primarily listed on the National Stock Exchange of India. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the pharmaceuticals market.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BTAD.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,7 %+1,5 %
    Communication Services+2,2 %−5,5 %+1,5 %
    Energy+0,9 %+5,2 %+0,1 %
    Health Care · THIS SECTOR+0,7 %−0,8 %−0,1 %
    Information Technology+0,2 %+8,1 %−0,5 %
    Consumer Discretionary+0,2 %+8,7 %−0,6 %
    Financials−0,3 %−2,8 %−1,0 %
    Consumer Staples−0,6 %+2,2 %−1,3 %
    Real Estate−0,7 %+10,9 %−1,4 %
    Industrials−1,1 %−0,3 %−1,9 %
    Utilities−1,9 %+28,2 %−2,6 %

    Developing storylines

    No tracked sagas currently linked to BTAD.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-07-27 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Beta Drugs Ltd (BTAD.NS) is a pharmaceutical company headquartered in India that operates within the Healthcare sector. The firm is primarily listed on the National Stock Exchange of India. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the pharmaceuticals market.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    (a) Capital structure and liquidity for Beta Drugs Ltd show no dilution risk, as shares outstanding remain unchanged between basic and diluted shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    (b) Profitability and returns data are not available for Beta Drugs Ltd, and no industry_config preferred metrics or cohort medians can be compared at this time.

    (c) Segment and geographic exposure details are not disclosed in the available data, and no revenue concentration metrics are provided to assess risk from specific markets or product lines.

    (d) Growth trajectory data is limited, as no outlook numeric deltas or revenue history are available to project future performance.

    (e) Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. Dilution risk is currently low, with no adjustments applied to valuation metrics.

    (f) No recent events, filings, or transcripts are available to inform the company's current strategic or operational direction.

    Key takeaways
    • Beta Drugs Ltd has no dilution risk based on current share structure.
    • Liquidity risk cannot be assessed due to missing balance-sheet data and no going-concern language in source documents.
    • No profitability or returns data is available for comparison with industry benchmarks.
    • No segment or geographic exposure details are disclosed, limiting visibility into revenue concentration risks.
    • No recent events or filings are available to inform strategic or operational direction.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    $1 361,60
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Beta Drugs Ltd Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BTAD.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-27 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage